In the BioHarmony Drug Report Database

"Preview" Icon

Apomorphine

Apokyn, Kynmobi (apomorphine) is a small molecule pharmaceutical. Apomorphine was first approved as Apokyn on 2004-04-20. It is used to treat parkinson disease in the USA. The pharmaceutical is active against D(2) dopamine receptor, D(3) dopamine receptor, and D(4) dopamine receptor. In addition, it is known to target D(1B) dopamine receptor, alpha-2A adrenergic receptor, alpha-2C adrenergic receptor, transient receptor potential cation channel subfamily A member 1, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C. Apokyn’s patents are valid until 2036-04-19 (FDA).

 

Trade Name

 

Apokyn, Kynmobi
 

Common Name

 

apomorphine
 

ChEMBL ID

 

CHEMBL53
 

Indication

 

parkinson disease
 

Drug Class

 

Image (chem structure or protein)

Apomorphine structure rendering